Stockscreener 앱 받기
26.59
4.21%
-1.17
시간 외 거래:
26.20
-0.39
-1.47%
전일 마감가:
$27.76
열려 있는:
$29.29
하루 거래량:
567.48K
Relative Volume:
2.42
시가총액:
$1.12B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+22.20%
1개월 성능:
+34.36%
6개월 성능:
+292.18%
1년 성능:
+55.95%
1일 변동 폭
$25.80
$29.73
1주일 범위
$18.33
$29.73
52주 변동 폭
$5.83
$29.73
Zenas Biopharma Inc Stock (ZBIO) Company Profile
명칭
Zenas Biopharma Inc
전화
857-271-2954
주소
852 WINTER STREET, SUITE 250, WALTHAM
ZBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
26.59 | 1.31B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-20 | 개시 | Wedbush | Outperform |
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2024-12-16 | 개시 | H.C. Wainwright | Buy |
| 2024-11-05 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-08 | 개시 | Citigroup | Buy |
| 2024-10-08 | 개시 | Guggenheim | Buy |
| 2024-10-08 | 개시 | Jefferies | Buy |
| 2024-10-08 | 개시 | Morgan Stanley | Overweight |
모두보기
Zenas Biopharma Inc 주식(ZBIO)의 최신 뉴스
Zenas Biopharma stock hits all-time high at 29.29 USD - Investing.com India
Zenas Biopharma stock hits all-time high at 29.29 USD By Investing.com - Investing.com South Africa
Zenas BioPharma (ZBIO) Is Up 32.5% After Securing Global Rights to Orelabrutinib in MS Deal - Yahoo Finance
Zenas BioPharma (NASDAQ:ZBIO) Sets New 1-Year High Following Analyst Upgrade - MarketBeat
Zenas BioPharma Inc Stock Analysis and ForecastSector Rotation Strategies & Watch Expert Picks Before They Rally - earlytimes.in
Will Zenas BioPharma Inc. stock go up soonTrade Entry Summary & Scalable Portfolio Growth Ideas - newser.com
Wedbush Issues Positive Forecast for Zenas BioPharma (NASDAQ:ZBIO) Stock Price - MarketBeat
HC Wainwright Reiterates Buy Rating for Zenas BioPharma (NASDAQ:ZBIO) - MarketBeat
Zenas BioPharma files automatic mixed securities shelf - MSN
Zenas BioPharma: Strategic Licensing and Clinical Advancements Justify Buy Rating - TipRanks
Rx Rundown: Novo Nordisk, Chiesi Group, Zenas Biopharma and more - Medical Marketing and Media
Zenas Biopharma (ZBIO) director Moulder buys $770k in shares By Investing.com - Investing.com South Africa
Insider Buying Spree: Zenas BioPharma Executives Make Bold Moves! - TipRanks
Zenas Biopharma (ZBIO) director Moulder buys $770k in shares - Investing.com India
Lu Hongbo buys Zenas Biopharma (ZBIO) shares worth $6m - Investing.com
Zenas BioPharma rises after Wedbush raises price target - MSN
Zenas BioPharma hits record high as brokerages raise PT - TradingView
Zenas BioPharma: Two Late-Stage Catalysts And A $2B InnoCare Deal (ZBIO) - Seeking Alpha
H.C. Wainwright maintains Zenas Biopharma stock Buy rating on pipeline expansion - Investing.com Canada
Strategic Expansion and Financial Strength Bolster Zenas BioPharma’s Growth Potential: Buy Rating Reaffirmed - TipRanks
Wedbush Raises Price Target on Zenas BioPharma to $40 From $35, Keeps Outperform Rating - MarketScreener
Risk vs reward if holding onto Zenas BioPharma Inc.Earnings Risk Summary & Expert Curated Trade Ideas - newser.com
Should you wait for a breakout in Zenas BioPharma Inc.July 2025 Retail & Risk Adjusted Swing Trade Ideas - newser.com
Zenas BioPharma (Nasdaq:ZBIO) Secures License for Three Autoimmune Candidates Including Orelabrutinib - Kalkine Media
Why Zenas BioPharma (ZBIO) Jumped 17.1% After Announcing $200M Shelf Filing and Major License Talks - simplywall.st
Zenas BioPharma and InnoCare Pharma Announce License - GlobeNewswire
Zenas Biopharma Inc Files For Mixed Shelf- SEC Filing - TradingView
Zenas gets global rights for Innocare BTK inhibitor in $2B+ deal - BioWorld MedTech
Zenas Biopharma Raises $120 Million To Secure Global Rights To Multiple Sclerosis Drug - inkl
Zenas BioPharma (NASDAQ:ZBIO) Receives "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Zenas Bio inks potential $2 billion licensing deal with China's InnoCare for autoimmune drug - Reuters
Zenas inks license agreement with InnoCare for 3 autoimmune programs - The Pharma Letter
Zenas looks to China to stock pipeline with 3 more immune drugs - BioPharma Dive
Zenas BioPharma (NASDAQ:ZBIO) Shares Gap UpWhat's Next? - MarketBeat
InnoCare Pharma's US Unit Grants Exclusive License of MS Drug to Zenas BioPharma - 富途牛牛
Zenas climbs on licensing deal with InnoCare (ZBIO:NASDAQ) - Seeking Alpha
Zenas Biopharma stock soars after securing rights to MS drug candidate - Investing.com
Zenas BioPharma Secures Licensing Deal with InnoCare - TipRanks
Waltham company forges $2B deal for MS drug - The Business Journals
InnoCare Pharma says unit entered exclusive license agreement & subscription agreement with Zenas BioPharma - MarketScreener
Zenas Biopharma licenses three autoimmune candidates from InnoCare - Investing.com
InnoCare, Zenas sign global licensing pact worth over $2 bln - MarketScreener
Zenas BioPharma Granted License for MS Drug Candidate in $2 Billion Deal - MarketScreener
Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis - The Manila Times
Innocare says unit signs license agreement with Zenas Biopharma - MarketScreener
INNOCARE, Zenas Forge Global Strategic Co-op & License Deal with Total Potential Value USD2B+ - AASTOCKS.com
Zenas BioPharma (NASDAQ:ZBIO) Trading 8.9% HigherHere's What Happened - MarketBeat
Ranking Zenas BioPharma Inc. among high performing stocks via toolsBear Alert & Low Risk High Win Rate Stock Picks - newser.com
Using Ichimoku Cloud for Zenas BioPharma Inc. technicalsWeekly Investment Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Advanced analytics toolkit walkthrough for Zenas BioPharma Inc.Weekly Market Outlook & Weekly High Return Stock Forecasts - newser.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Investors to Connect - ACCESS Newswire
Zenas Biopharma Inc (ZBIO) 재무 분석
Zenas Biopharma Inc (ZBIO)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Zenas Biopharma Inc 주식 (ZBIO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | Director |
Oct 07 '25 |
Buy |
19.00 |
316,219 |
6,008,161 |
2,209,025 |
| Lu Hongbo | Director |
Oct 07 '25 |
Buy |
19.00 |
263,160 |
5,000,040 |
321,983 |
| MOULDER LEON O JR | Chief Executive Officer |
Feb 18 '25 |
Buy |
6.67 |
25,000 |
166,750 |
266,155 |
| Xiao Ting | Director |
Feb 07 '25 |
Buy |
7.76 |
10,000 |
77,600 |
47,000 |
| MOULDER LEON O JR | Chief Executive Officer |
Dec 04 '24 |
Buy |
9.98 |
45,000 |
449,100 |
241,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Dec 03 '24 |
Buy |
10.76 |
25,000 |
269,000 |
196,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Nov 18 '24 |
Buy |
15.00 |
7,500 |
112,500 |
168,655 |
| MOULDER LEON O JR | Chief Executive Officer |
Nov 19 '24 |
Buy |
14.57 |
2,500 |
36,425 |
171,155 |
5.74%
자본화:
|
볼륨(24시간):